RMD - Educational Analysis * US Equities
Educational Analysis * US Equities

RMD

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerRMD
CategoryEducational primer
Last reviewedNovember 9, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

ResMed Inc. (RMD) sits in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. Its core business is digital health and cloud-connected medical devices that treat sleep and breathing disorders: CPAP/APAP/bilevel/ventilation devices, masks, diagnostics, dental devices, and the software that ties them together. The company also sells cloud-based Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers, and it distributes products in more than 140 countries.

The company’s most recent 10-K shows two operating segments: Sleep and Breathing Health and Residential Care Software. In fiscal 2026, devices generated roughly 51% of net revenue, masks/diagnostics/accessories contributed about 37%, and software accounted for roughly 12%. That revenue mix matters because the mask/accessory line and software line typically carry higher recurring characteristics than device sales, which can make revenue more durable over time.

The financial profile backs up the idea of a defendable franchise. ResMed’s net margin is 27.8% and its return on equity is 25.1% — both figures point to pricing power, operational efficiency, and/or entrenched customer relationships. The installed base of more than 35 million cloud-connected devices on AirView and over 12 million patients registered on myAir creates a switching-cost dynamic that supports those margins.

Financial posture

ResMed currently carries a market capitalization of $33.1 billion and trades at a P/E ratio of 21.4. For a healthcare device and software company, that valuation is neither bargain-bin nor stretched; it sits in a range where expectations are real but not euphoric.

Profitability metrics are clearly the standout feature. A 27.8% net margin and 25.1% ROE place ResMed well above the typical capital-intensive medical-device peer group, which often runs on thinner hardware margins. A beta of 0.76 indicates the stock has historically moved with less volatility than the broader market, consistent with a stable, recurring-revenue healthcare business.

As of the latest snapshot, the stock is at $235.30, with the 50-day EMA at $232.63 and RSI at 48.3. That places price roughly in line with its short-term average and in neutral momentum territory, neither overbought nor oversold.

Strategic priorities & outlook

ResMed’s most recent 10-K outlines a clear near-term playbook centered on its core sleep and breathing franchise. Management wants to grow and differentiate the sleep apnea portfolio by integrating AI/ML into devices, simplifying care pathways, and expanding home diagnostics — including the NightOwl platform and the recently acquired VirtuOx IDTF business.

On the market-development side, the company is investing in awareness and education targeted at patients, physicians, and special-interest groups for sleep apnea, COPD, and related comorbidities. It also wants to push into broader sleep and breathing health adjacencies such as COPD, neuromuscular disease, and restless legs syndrome (the latter via the Noctrix acquisition).

Operationally, ResMed is building an integrated, intelligent digital-health ecosystem delivered at home, anchored by AirView remote monitoring and the myAir patient engagement platform. At the filing date, the company had approximately 11,370 employees, more than 35 million cloud-connected devices on AirView, and over 12 million patients registered on myAir.

One notable portfolio move: in June 2026, ResMed agreed to sell its MatrixCare business for $490 million in cash to sharpen focus on core sleep, breathing, and connected home-based healthcare. The transaction is expected to close in the first quarter of fiscal 2027, which could simplify the story and remove a non-core segment from the mix.

Macro & geopolitical exposure

Because ResMed is classified as Medical – Instruments & Supplies, it faces the standard macro and geopolitical exposures of the healthcare-device industry. The most important are regulatory and reimbursement risk: product approvals, FDA enforcement, and CMS or private-payer coverage decisions can move the top line faster than unit demand. Any change in reimbursement rates for CPAP or oxygen therapy would directly affect the U.S. market, which is still the largest revenue pool for these devices.

Trade policy and supply chain also matter. Medical device manufacturers source electronic components, sensors, and resins globally, and tariffs or logistics disruptions can compress margins. With sales in more than 140 countries, currency translation is another real factor; a stronger U.S. dollar reduces the value of overseas revenue when converted back.

A sector-specific demand consideration is the rise of GLP-1 therapies for obesity and related conditions. Since obesity is a major driver of obstructive sleep apnea, some investors worry that effective weight-loss drugs could eventually dampen CPAP demand. The Nov. 5 Barron’s headline — “Don’t Lose Sleep Over GLP-1s: Why ResMed Is a Bargain” — shows this debate is front and center, but the data itself does not resolve whether GLP-1s will help, hurt, or simply shift the patient mix over time.

Recent developments

ResMed has stayed in the news heading into November 2026. On November 6, Defense World published a financial comparison between ResMed and Terumo (ResMed vs. Terumo Financial Comparison). On November 5, Barron’s ran the piece “Don’t Lose Sleep Over GLP-1s: Why ResMed Is a Bargain,” tackling the GLP-1 narrative directly. The same day, Seeking Alpha listed ResMed among its “Top 10 High Growth Dividend Stocks For November 2026.” Earlier, on November 2, Motley Fool offered “ResMed: 3 Key Takeaways for Long-Term Investors.”

These headlines share a common theme: analysts and commentators are evaluating whether ResMed’s profitability, recurring revenue, and digital-health moat can offset longer-term concerns about GLP-1 disruption. None of the headlines change the underlying numbers, but they explain why the stock’s valuation — P/E 21.4, net margin 27.8% — is getting extra scrutiny.

Earnings behavior & post-earnings drift

ResMed’s earnings record has been strong on the headline numbers, yet tricky for short-term traders. Over the last eight reported quarters, the company has beaten earnings expectations 7 out of 8 times — an 88% beat rate — with an average earnings surprise of 3.1%. That suggests the management team is either conservative with guidance or consistently out-executes the consensus.

But the post-earnings price action has not rewarded beats. The average 5-day price move after earnings across those quarters is -0.84%, classified as a downward post-earnings drift. In other words, “beat equals pop and hold” has not been a reliable playbook with ResMed.

The most recent four quarters illustrate the disconnect clearly:

  • October 29, 2026: EPS came in at $2.91 versus the $2.69 estimate, an 8.2% surprise. Yet the stock fell 9.05% the next day and was down 5.35% over the following five days.
  • August 6, 2026: EPS was $2.95 versus $2.89 (2.1% surprise). The stock dropped 5.06% the next day, though it recovered to a +1.57% five-day drift.
  • April 30, 2026: EPS of $2.86 beat $2.80 by 2.1%. The next-day move was -4.11%, with a five-day drift of -3.24%.
  • January 29, 2026: EPS of $2.81 beat $2.74 by 2.6%. The stock barely moved the next day (+0.27%) but drifted +3.66% over the following five sessions.

One plausible explanation is that the unofficial expectation was higher than the published consensus, especially after a string of beats. When high expectations are already priced in, even a solid beat can trigger profit-taking. ResMed next reports on January 28, 2027, after the close, with a current consensus EPS estimate of $3.03.

Frequently Asked Questions

What does ResMed primarily sell?

ResMed is a digital-health and medical-device company focused on sleep and breathing health. Its products include CPAP, APAP, bilevel, and ventilation devices, masks, diagnostics, dental devices, and cloud-connected software such as AirView and myAir. It also sells Residential Care Software to home health, hospice, and senior-care providers.

Why has ResMed stock sometimes fallen after beating earnings estimates?

Over the last eight quarters ResMed has beaten expectations 88% of the time with an average surprise of 3.1%, yet the average five-day post-earnings drift is -0.84%. The unofficial expectation may simply be higher than the published consensus, so a beat can still trigger profit-taking — especially when the GLP-1 narrative is already weighing on sentiment.

What strategic changes is ResMed highlighting in its 10-K?

The 10-K emphasizes growing the core sleep apnea business through AI/ML integration and home diagnostics, expanding awareness for sleep apnea and COPD, and pushing into adjacent conditions such as neuromuscular disease and restless legs syndrome. ResMed also agreed to sell its MatrixCare business for $490 million in June 2026 to sharpen its focus on connected sleep and breathing care at home.

For a deeper dive into how sell-side analysts, institutional holders, and quantitative models are currently weighing these factors, take a look at the full institutional verdict on ResMed before drawing any conclusions.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 9, 2026
ResMed Inc. · Healthcare / Medical - Instruments & Supplies
$33.1BMarket cap
21.4P/E
27.8%Net margin
25.1%ROE
88%Beat rate, last 8Q
3.1%Avg EPS surprise
-0.84%Avg 5-day move after earnings
2027-01-28Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-10-29$2.91$2.69+8.2%-9.05%-5.35%
2026-08-06$2.95$2.89+2.1%-5.06%+1.57%
2026-04-30$2.86$2.8+2.1%-4.11%-3.24%
2026-01-29$2.81$2.74+2.6%+0.27%+3.66%
2025-10-30$2.55$2.51+1.6%--
2025-07-31$2.55$2.46+3.7%--

Previous RMD editions

Beyond the primer

Get the institutional verdict on RMD

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the RMD verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.